Voyager Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Voyager Therapeutics, Inc. (VYGR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.69 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.72, a 51.56% decline year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.68, a 1.72% increase year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $7.55, a 55.67% increase year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.85, a 34.64% decline year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.10, a 47.10% decline from fiscal 2024.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.75, a 9.67% decline from fiscal 2023.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.58, a 65.96% increase from fiscal 2022.
- Voyager Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.17, a 18.20% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.69 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $4.10 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $4.10 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $4.13 10-Q · filed 2025-08-06 | ||||
| 2025-03-31 | $3.72 10-Q · filed 2026-05-07 | $4.27 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $7.75 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $7.79 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $7.81 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $7.68 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $8.58 10-K · filed 2024-02-28 | ||||
| 2023-09-30 | $8.64 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | $8.32 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $7.55 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $5.17 10-K · filed 2023-03-07 | ||||
| 2022-09-30 | $5.14 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $4.95 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $4.85 10-Q · filed 2022-05-04 | ||||
| 2021-12-31 | $6.32 10-K · filed 2022-03-08 | ||||
| 2021-09-30 | $6.57 10-Q · filed 2021-11-02 | ||||
| 2021-06-30 | $6.62 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $7.42 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $11.87 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $12.07 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $12.33 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $12.88 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $15.42 10-K · filed 2020-03-03 | ||||
| 2019-09-30 | $15.50 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $14.70 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $9.32 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $20.78 10-K · filed 2019-02-26 | ||||
| 2018-09-30 | $21.54 10-Q · filed 2018-11-07 | ||||
| 2018-06-30 | $23.88 10-Q · filed 2018-08-07 | ||||
| 2018-03-31 | $24.76 10-Q · filed 2018-05-10 | ||||
| 2017-09-30 | $12.16 10-Q · filed 2017-11-02 | ||||
| 2017-06-30 | $11.51 10-Q · filed 2017-08-08 | ||||
| 2017-03-31 | $11.94 10-Q · filed 2017-05-09 | ||||
| 2016-09-30 | $11.83 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $11.58 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $11.18 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |